Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes

Thrombosis and Haemostasis

Volumn 110, Issue 1, 2013, Pages 11-13

  Huber, Kurt ^a   Lip, Gregory Y H Lip ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; PRASUGREL; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; DRUG DOSE REDUCTION; DRUG MEGADOSE; FIBRINOLYTIC THERAPY; HUMAN; LOADING DRUG DOSE; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE CORONARY SYNDROME; ADENOSINE; CLINICAL TRIALS AS TOPIC; EUROPE; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; THIOPHENES; TICLOPIDINE; UNITED STATES;

EID: 84879663575     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-06-0453     Document Type: Article

References (11)

1. Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054.
2. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST Elevation Myocardial Infarction (Updating the 2007Guideline and Replacing the 2011 Focused Update). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-681.
3. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST- Elevation Myocardial InfarctionA Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78-e140.
4. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
5. Serebruany V, DiNicolantonio J. Mismatch Between the European and American Guidelines on Oral Antiplatelet P2Y12 Inhibitors After Acute Coronary Syndromes. Thromb Haemost 2013; 110:5-10.
6. Wiviott SD, Braunwald E, McCabe CH, et al. Pra- sugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
7. Wallentin L, Becker R, Budaj A, et al. for the PLATO Investigators. Ticagrelor versus clopido-grel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
8. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932.
9. Mahaffey KW, Wojdyla DM, Carroll K, et al. PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124: 544-554.
10. Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Thromb Haemost 2011; 105: 763-765.
11. Wallentin L, Becker RC, James SK, et al. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary